BridgeBio Pharma (BBIO) Common Equity (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Common Equity data on file, last reported at -$2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 39.06% year-over-year to -$2.3 billion; the trailing twelve-month figure through Mar 2026 stood at -$2.3 billion (down 39.06% YoY), and the FY2025 full-year result was -$2.1 billion, down 42.41% from the prior year.
• Common Equity retreated to -$2.3 billion in Q1 2026, from -$2.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$1.0 billion in Q2 2022 to a low of -$2.3 billion in Q1 2026.
• A 5-year average of -$1.4 billion and a median of -$1.2 billion in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 167.36% in 2022 and gained 19.86% in 2024, its largest moves.
• Tracing BBIO's Common Equity over 5 years: stood at -$1.2 billion in 2022, then dropped by 8.02% to -$1.3 billion in 2023, then declined by 8.54% to -$1.5 billion in 2024, then plunged by 42.41% to -$2.1 billion in 2025, then slipped by 9.75% to -$2.3 billion in 2026.
• Business Quant data shows BBIO's Common Equity at -$2.3 billion in Q1 2026, -$2.1 billion in Q4 2025, and -$1.9 billion in Q3 2025.